Accurate Biomarker Testing Key to Experimental MetMAb in Lung Cancer
June 14, 2011|Oncology Practice
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Dr. Spigel observed that no new safety concerns emerged in the trial, although patients treated with MetMAb had more peripheral edema that was largely low grade, reversible, and manageable.
A phase III study testing MetMAb plus erlotinib in Met diagnostic–positive patients is expected to start enrolling this year, he said.
Dr. Spigel disclosed a consultant/advisory role with Genentech, which sponsored the study. His coauthors disclosed financial relationships with several firms including employment with Genentech.
